Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: TomOrt who wrote (26688)	11/27/1998 9:13:00 AM
From: Henry Niman	Respond to of 32384

Tom, Thanks for the heads up. I believe that Jim McCamant will be on CNBC this morning at 9:50.

To: TomOrt who wrote (26688)	11/27/1998 10:07:00 AM
From: Henry Niman	Read Replies (3) \| Respond to of 32384

Jim McCamnat was just on CNBC. Talked mostly in general terms and only smaller company mentioned was ISIP (CHIR was mentioned as a diversified Biotech and CNTO was mentioned as having some competition for Remicade for Crohn's disease from ISIP's product which was a couple of years away from approval). In lead in Joe Kernan mention Herceptin (GNE) and Enbrel (IMNX) and Mccamant indicated that the sectors progress had been steady, but price really hasn't moved much. Indicated that Biotech was like internet - with no limits and predicted a major price move soon. Joe Kernan mentioned prevention as a boon to quality of life and economy and McCamant mentioned drugs that allowed workers get back to work (example was Enbrel for RA). Mentioned that Gene Therapy was out of favor, so prices were low and also mentioned need for basket of stocks if 3rd tier companies were being considered.

To: TomOrt who wrote (26688)	11/30/1998 6:43:00 PM
From: kha vu	Read Replies (1) \| Respond to of 32384

biz.yahoo.com news of lgnd

To: TomOrt who wrote (26688)	12/1/1998 12:02:00 AM
From: kha vu	Read Replies (1) \| Respond to of 32384

SAN DIEGO--(BW HealthWire)--Nov. 30, 1998--Ligand Pharmaceuticals Incorporated (Nasdaq:LGND - news) announced today that the U.S. Food and Drug Administration (FDA) has issued an approvable letter regarding the New Drug Application (NDA) for Panretin® gel (alitretinoin) 0.1% for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma (KS). The final approval is pending review of additional chemistry information submitted by the Company as requested by the FDA and upon final labeling agreement. The Company expects following the approvable letter to receive a final action letter on marketing approval by the end of December. ''We are pleased to receive the FDA approvable letter following only nine days after the 8 to 1 vote from the Oncologic Drugs Advisory Committee recommending NDA approval to the FDA,'' said Ligand Chairman, President and CEO David E. Robinson. ''We look forward to continuing to work closely with the agency to finalize labeling such that we can supply the product to patients with KS in the U.S. as soon as possible.'' Panretin gel was assigned priority review status by the FDA, which requires the FDA to review and act on the NDA within six months of the NDA submission date. The action letter may indicate approval or may detail specific deficiencies of the NDA and the actions necessary to place the application in condition for approval. The FDA received the NDA for Panretin gel on May 27, 1998 and the approvable letter was received by Ligand on Nov. 25, 1998. Since 1989, Ligand Pharmaceuticals Incorporated has established a leadership position in gene transcription technology, particularly intracellular receptor (IR) technology and STATs technology. Ligand has applied IR and STATs technology to the discovery and development of small molecule drugs to enhance therapeutic and safety profiles and to address major unmet patient needs in cancer, women's and men's health, skin diseases, osteoporosis, and metabolic, cardiovascular and inflammatory diseases. This news release may contain certain forward looking statements by Ligand and actual results could differ materially from those described as a result of factors including, but not limited to, the following. There can be no assurance any product in the Ligand pipeline will be successfully developed, that results from more advanced clinical trials will be consistent with earlier results, that drug candidates will show efficacy in all indications currently being studied, that regulatory approvals will be granted in a timely manner, or at all, that patient physicians' acceptance of these products will be achieved, or that Ligand will successfully hire a sales force. Ligand undertakes no obligation to update the statements contained in this press release after the date hereof. Note: If you would prefer to receive Ligand's press releases via e-mail please inform us at investors@ligand.com and request to be placed on our priority e-mail list. You may visit Ligand's website at ligand.com. Contact: Ligand Pharmaceuticals Incorporated Mary Kenny, 619/550-7536